Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
Brief description of study
The purpose of this research study is to assess the safety of daratumumab (Darzalex®) and whether it may reduce levels of antiphospholipid antibodies, a blood protein in the immune system that mistakenly creates antibodies that attack tissues in the body, in patients with antiphospholipid syndrome (APS).
Clinical Study Identifier: s22-01215
ClinicalTrials.gov Identifier: NCT05671757
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
